Daiichi Sankyo is the second largest pharma company in Japan, developing small molecules & biologics for various diseases and was came into existence in 2005, through the merger of Sankyo Co., Ltd. and Daiichi Pharmaceutical Co., Ltd.
- In Sep 2020, Rain Therapeutics Inc. acquired worldwide rights to a clinical stage, oral small molecule, MDM2 inhibitor, DS-3032 /milademetan (now RAIN-32 ) from Daiichi Sankyo Company. RAIN-32 has been evaluated in patients with various solid tumors, acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Financial terms remains undisclosed.
- In July 2020, AstraZeneca entered into its second collaboration with Daiichi Sankyo, for the development of DS-1062, Daiichi Sankyo’s proprietary trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC), Under the terms, AstraZeneca paid Daiichi Sankyo an upfront payment of $1 bn and additional conditional amounts of up to $1 bn for the successful achievement of regulatory approvals and up to $4bn for sales-related milestones. AstraZeneca will equally share the cost of development and commercialization of DS-1062 along with any profits earned from its sale, except for Japan where Daiichi will have full control.
- In Mar 2019, AstraZeneca signed global collaboration deal with Daiichi Sankyo for its proprietary antibody-drug conjugate trastuzumab deruxtecan (DS-8201), to jointly develop and commercialize trastuzumab deruxtecan worldwide, except in Japan where Daiichi Sankyo will maintain exclusive rights. Under the terms, AstraZeneca paid Daiichi Sankyo an upfront payment of $1.35bn and contingent payments of up to $5.55bn including $3.8bn for potential successful achievement of future regulatory and other milestones, as well as $1.75bn for sales-related milestones.
- In Nov 2019, BioInvent entered into a license and discovery agreement with Daiichi Sankyo (TSE: 4568) for the development of therapeutic antibodies against multiple targets. Under the terms, Daiichi was granted broad access to BioInvent’s discovery and development technology platform and in house antibody expertise.
- In July 2018, Daiichi Sankyo and Glycotope entered into an exclusive worldwide licensing agreement to develop an antibody drug conjugate (ADC) by combining Daiichi Sankyo’s proprietary ADC technology with Glycotope’s investigational tumor- associated TA-MUC1 antibody gatipotuzumab. Under the terms,
- Daiichi Sankyo has worldwide exclusive rights to develop and commercialize gatipotuzumab as an ADC, further financial terms remains undisclosed.
- In Aug 2017, Boston Pharmaceuticals acquired worldwide developing & marketing rights of Daiichi Sankyo’s novel RET inhibitor, DS-5010. Financial terms of the agreement remains undisclosed.
Daiichi is in agreement with Amgen for the commercialization of Denosumab/Prolia®/AMG 162 (approved by FDA as a treatment to increase bone mass in patients). - Daiichi Sankyo also has an exclusive rights for Japan to develop and market Nimotuzumab/DE 766 (currently in PH III for solid tumors), which was licensed from CIMYM Biosciences.
- In Jan 2014, Daiichi, Virtici LLC and Celdara Medical entered into a collaboration to jointly investigate novel therapeutic candidate to further strengthen the Daiichi developmental pipeline across multiple therapeutic areas.
- In April 2014, Daiichi signed an agreement with Agendia to use its oncology biomarker technology in the assessment of novel pharmaceuticals currently researched in certain Daiichi Sankyo clinical trials.
- In Apr 2013, ArQule terminated license and co-commercialization agreement with Daiichi for ARQ 092 and regain all the development rights of the drug.
- In 2013, Odonate acquired licensed rights to tesetaxel in all major markets from Daiichi Sankyo, the original inventor of the product and Genta Incorporated. Prior to Odonate, both Daiichi Sankyo and Genta conducted initial clinical studies of tesetaxe.
Page 2 of 3
